Wave Life Sciences Initiates Phase 2a Trial for WVE-007 in Obesity
2 reports, 1 independent
Updated Wed 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA product, in combination with tirzepatide for adults with obesity. The company plans to use the trial to assess WVE-007 in monotherapy, combination therapy, and as a post-incretin maintenance therapy to prevent weight regain.
From finanznachrichten.de
Why it matters
Preclinical and clinical information suggests WVE-007 may enhance fat loss while preserving muscle mass compared to incretins used alone. The company is also evaluating WVE-007 for MASH indications.
From finanznachrichten.de
Who's involved
- Wave Life SciencesBiotechnology company conducting the clinical trial for WVE-007
Keep exploring
The entities involved
-
Wave Life Sciences
biotechnology company
-
mash
fast genome and metagenome distance estimation using MinHash
Nothing else this week.